Jan de Lange1, Hans P van den Akker, Helen Klip. 1. Department of Oral and Maxillofacial Surgery, Academic Medical Center/Academic Center for Dentistry (ACTA), University of Amsterdam, The Netherlands. kaakchirurgie@isala.nl
Abstract
BACKGROUND: The central giant cell granuloma (CGCG) of the jaw is a rare benign tumor with an unknown etiology. Epidemiologic data on CGCGs in a general population are not available, nor are data on the overall outcome of surgical therapy. In this article, an overview of these aspects in the Dutch population from January 1, 1990, until January 1, 1995, is presented. METHODS: All CGCGs that were diagnosed and surgically treated in The Netherlands from 1990 until 1995 were evaluated. RESULTS: The incidence is 0.00011%, and the disease-free survival after surgical therapy after 5 years is 76.1%. There is a significantly higher recurrence rate in young males, which cannot be explained by clinical signs and symptoms of the lesion. CONCLUSION: The CGCG is a rare affliction with a high recurrence rate after surgical therapy, especially in young males. Copyright 2004 Wiley Periodicals, Inc.
BACKGROUND: The central giant cell granuloma (CGCG) of the jaw is a rare benign tumor with an unknown etiology. Epidemiologic data on CGCGs in a general population are not available, nor are data on the overall outcome of surgical therapy. In this article, an overview of these aspects in the Dutch population from January 1, 1990, until January 1, 1995, is presented. METHODS: All CGCGs that were diagnosed and surgically treated in The Netherlands from 1990 until 1995 were evaluated. RESULTS: The incidence is 0.00011%, and the disease-free survival after surgical therapy after 5 years is 76.1%. There is a significantly higher recurrence rate in young males, which cannot be explained by clinical signs and symptoms of the lesion. CONCLUSION: The CGCG is a rare affliction with a high recurrence rate after surgical therapy, especially in young males. Copyright 2004 Wiley Periodicals, Inc.